VIPER-101
T-cell lymphoma
Phase 1Active
Key Facts
About ViTToria Biotherapeutics
ViTToria Biotherapeutics is a private, clinical-stage biotech founded in 2021, advancing a novel CAR T-cell therapy platform called Senza5. The company's lead program, VIPER-101, is in a Phase 1 trial for T-cell lymphoma, representing a move beyond the B-cell cancers addressed by current approved CAR-Ts. ViTToria's technology aims to overcome key limitations of existing cell therapies—including relapse, toxicity, and manufacturing complexity—by modulating CD5 signaling and utilizing a rapid 5-day manufacturing process. The leadership team combines deep expertise in immunology, drug development, and company building.
View full company profile